Background and purpose: Chronic cluster headache is a rare, highly disabling primary headache condition. When medically intractable, occipital nerve stimulation can offer effective treatment. Open-label series have provided data on small cohorts only. Methods: We analyzed 51 subjects to evaluate the long-term outcomes of highly intractable chronic cluster headache with occipital nerve stimulation. Patients with intractable chronic cluster headache were implanted with occipital nerve stimulators during the period 2007-2014. The primary endpoint was improvement in daily attack frequency. Secondary endpoints included attack severity, attack duration, quality-of-life measures, headache disability scores and adverse events. Results: We studied 51 patients [35 males; mean age at implant 47.78 (range 31-70) years; mean follow-up 39.17 (range 2-81) months]. Nineteen patients had other chronic headache types in addition in chronic cluster headache. At final follow-up, there was a 46.1% improvement in attack frequency (P < 0001) across all patients, 49.5% (P < 0.001) in those with cluster headache alone and 40.3% (P = 0.036) in those with multiple phenotypes. There were no significant differences in response in those with or without multiple headache types. The overall response rate (defined as at least a 50% improvement in attack frequency) was 52.9%. Significant reductions were also seen in attack duration and severity. Improvements were noted in headache disability scores and quality-of-life measures. Triptan use of responders dropped by 62.56%, resulting in significant cost savings. Adverse event rates were highly favorable. Conclusion: Occipital nerve stimulation appears to be a safe and efficacious treatment for highly intractable chronic cluster headache even after a mean follow-up of over 3 years.
Introduction
Cluster headache is a primary headache disorder characterized by bouts during which patients experience multiple attacks of severe unilateral pain associated with cranial autonomic features [1] . The condition is said to be chronic when attacks occur for over 1 year with remissions lasting <1 month. Cluster headache has a prevalence of around 0.1% [2] with 10-15% of this group suffering chronic cluster headache (CCH) [3] .
Cluster headache can be successfully treated with a range of oral and injectable medications. However, a proportion of patients with CCH are intractable to all available medications. Although a unifying definition of refractory CCH is still awaited, guidelines from Goadsby et al. [4] suggest that patients meet diagnostic criteria for CCH and have failed at least four classes of drugs from verapamil, lithium, methysergide melatonin, topiramate or gabapentin, with at least two from the first three agents. More recently, the European Headache Federation defined refractory CCH as patients meeting International Classification of Headache Disorders-3beta criteria who continue to suffer from at least three severe attacks per week despite adequate trials of at least three of the following: verapamil, lithium, oral or intravenous steroids, greater occipital nerve blockade, topiramate, methysergide, ergots, civamide or long-acting triptans [5] . Due to the highly disabling nature of intractable CCH, destructive surgical approaches to treatment have been investigated with disappointing results. Neurostimulation techniques involving peripheral and central targets have now emerged as promising therapies. Peripheral stimulation of the occipital nerve has been investigated as a potentially useful treatment for chronic migraine (CM) in a limited number of randomized control studies [6] [7] [8] and for CCH in a number of small open-label series [9] [10] [11] [12] [13] [14] [15] [16] .
We report the long-term follow-up of 51 patients with intractable CCH treated with occipital nerve stimulation (ONS).
Materials and methods

Patients
Patients with intractable CCH seen in the headache clinic at the National Hospital for Neurology and Neurosurgery (Queen Square, London, UK) were offered ONS. Patients were reviewed and operated on by a single multidisciplinary headache team, consisting of headache specialists, neurosurgeons and headache specialist nurses with access to psychology and psychiatry services. Implants took place over the period from October 2007 to June 2014. Follow-up visits occurred every 3 months for the first year and then every 6-12 months thereafter. All patients fulfilled the International Classification of Headache Disorders, 2 nd edition and revised International Classification of Headache Disorders-3beta diagnostic criteria for CCH as well as the proposed criteria for intractable CCH [3, 4] . We offered ONS to patients with intractable CCH under the supervision of our institution's Clinical Effectiveness Supervisory Committee with arrangements for clinical governance, consent and audit. The procedure was provided on the basis of a 'humanitarian intervention'. In addition, ethics board approval for data collection and publication was granted by Northwick Park Hospital Research Ethics Committee (Hampstead, London, UK).
Surgical procedure
The ONS systems were implanted as described elsewhere [17] . Bilateral octad electrodes were placed in all patients ( At initial programming, frequency was set at 60 Hz with a pulse width of 240 ls. Polarity of the electrodes was adjusted during follow-up visits to ensure comfortable bilateral paraesthesia in the occipital region. Patients used continuous stimulation but were able to adjust the amplitude. Medications were changed at the discretion of the headache specialist.
Data collection
Data were collected prospectively and entered onto a clinical database (Microsoft Excel, Microsoft Corporation, Redmond, WA, USA). Data including demographics, diagnosis, attack frequency, previous and current treatments, and adverse events were recorded. Patients prospectively completed headache diaries recording the frequency, severity on a verbal rating scale (0, no pain to 10, extreme pain) and duration of cluster headache attacks for 1 month prior to implant and 2 weeks prior to each follow-up visit. Diaries were used to calculate mean daily attack frequency, severity and duration over these periods of time. Where multiple headache types were present, patients completed separate diaries for each.
Migraine Disability Assessment Score (MIDAS) and Headache Impact Test 6 (HIT-6) scores were recorded pre-and post-ONS to monitor headacherelated disability. Although MIDAS has not been validated for its use in CCH, it has been used extensively The primary outcome measure was improvement in mean daily attack frequency at final follow-up compared with baseline. Response was defined as a 50% or more reduction in mean daily attack frequency. Secondary outcome measures included attack severity, attack duration, headache-related disability scores, affective measures and quality-of-life scores.
Statistics
All statistical analyses were conducted using IBM SPSS Statistics version 22 (IBM Corp. Int., Armonk, New York, USA). A last observation carried forward technique was used in the case of missing data. Descriptive statistics were summarized as appropriate. Data are presented as mean AESD, range and frequencies. Paired and independent t-tests were used to compare treatment effect as appropriate. All statistical tests were two-sided with a significance level of 95%.
Results
Patient demographics
Thirty-five men and 16 women with a mean age of 47.78 (range 31-70) years were implanted. The mean duration of CCH at implantation was 7.88 (range 2-43) years. The mean number of medications prior to implant was 12.57 AE 2.91 (range 7-21) (Table S1 ). Nineteen patients (37.3%) had other chronic headaches in addition to CCH: 13 had CCH and CM, three had CCH and short-lasting unilateral neuralgiform headache attacks (SUNHAs) and three had CCH, CM and SUNHA. All kept separate diaries for each phenotype throughout follow-up. Table 2 provides demographic data for the cohort.
Whole cohort
The mean follow-up time was 39.17 (range 2-81) months. At follow-up, four patients had their implants removed, three for lack of efficacy and one for intractable neck pain secondary to lead tethering. Figure 1a shows the percentage improvement in daily attack frequency over the follow-up period. At final follow-up, 52.9% (n = 27) of patients achieved at least a 50% reduction in daily attack frequency (i.e. were classed as responders). Mean daily attack frequency fell by 46.1% (AE43.7) (P < 0.001). Over the course of follow-up, 47.1% (n = 24) of patients reported over 6 months of continuous freedom from pain. The mean duration of pain freedom was 16.25 (range 6-48) months. Significant reductions were also seen in attack intensity (26.4%) and duration (43.3%) ( Table 3) . Across the cohort, significant improvements were observed in MIDAS (À34.92), HIT-6 (À7.05), HAD-A (À2.04), HAD-D (À2.82) and BDI-II (À4.77) scales. Quality-of-life scores showed improvements but only that in the SF-36 mental composite score was significant (Table 4) . Non-responders to ONS failed to show any improvement in any headache disability, affect or quality-of-life scores. Responders showed CCH, chronic cluster headache; CM, chronic migraine; GON, greater occipital nerve; ONS, occipital nerve stimulation; SUNA, short-lasting unilateral neuralgiform headache attacks with autonomic features; SUNCT, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing.Data are given as mean AESD or n (%).
significant improvements in all headache disability scores and affective scores as well as SF-36 mental composite score (Table S2 ). The patient estimate of overall CCH improvement was 53.7% (AE38.60). Differences in outcomes of responders and non-responders are shown in Table S3 .
Chronic cluster headache alone
In the 32 patients with CCH alone, mean follow-up time was 42.59 (range 2-81) months. Figure 1b shows the change in daily attack frequency over follow-up. A 50% response was observed in 53.1% (n = 17) of patients. Mean daily attack frequency was reduced by 49.5% (AE43.84%) (P < 0.001). Significant improvements were also seen in daily attack severity (25.0%) and duration (43.2%) ( Table 3 ). Significant change was seen in MIDAS (À47.66), HIT-6 (À7.62), HAD-A (À2.03), HAD-D (À2.81) and BDI-II (À6.43) scales. However, no significant improvements were observed in any quality-of-life measures (Table 4) .
Multiple phenotypes including CCH
In the 19 patients with multiple headache phenotypes, the mean follow-up time was 33.42 (range 13-76) months. The 50% response rate at final follow-up was 52.6% (n = 10), which was not significantly different to that of CCH alone (P = 0.973). Change in daily attack frequency over follow-up is shown in Fig. 1b .
No difference was seen in change in daily attack frequency between the groups at any time-point. Significant improvements were also seen in attack intensity (28.8%) and duration (43.5%) ( Table 3) . In responders, four of eight patients with CM showed improvement (defined as >30% improvement in moderate-to-severe headache days) and three of four patients with SUNHA also showed improvement (defined as ≥50% reduction in daily attack frequency). In non-responders, five of eight patients with CM improved with ONS.
Those with multiple phenotypes showed significant improvements in HIT-6 (À6.10) and Euro-QoL visual analogue score (10.38) scales but in no other disability, affect or quality-of-life measurement (Table 4) .
Triptan use
With regard to triptans, nine patients stopped and 13 were able to decrease their use by more than 50%. Monthly triptan use was 36.82 AE 32.7 (range 0-112) prior to and 19.51 AE 33.07 (range 0-120) post-ONS (P < 0.001). The average cost in the UK for injectable Sumatriptan is currently £20.50 per dose, translating to a saving of £407.19 AE 514.98 (range £0-1722) per patient per month. Responders averaged a monthly reduction of 29.37 AE 25.76 doses (P < 0.001), resulting in a saving of £604.37 AE 519.52 per patient per month (Table S3c) .
Preventative medication use
Twenty-seven patients were taking preventative medications at baseline. Four patients were able to stop all preventative medications and, in total, 17 patients made reductions to their drugs.
Time to effect and recurrence of attacks
Time to first reported 50% improvement in cluster headache attacks was recorded in 37 patients with a mean of 6.86 AE7.33 (range 1-42) months. Time to reach maximum reported improvement was 21.69 AE15.06 (range 2-54) months. Nineteen patients had their ONS switched off at some point (13 due to battery depletion, five due to lack of efficacy and one due to explantation). The mean time of ONS switch-off in these subjects was 7.29 (range 2-18) months. In 12 of these patients (63.2%), CCH worsened within a mean of 6.57 weeks of switch off (range 1-12 weeks).
Stimulation settings
A range of settings was employed in order to achieve the widest area of occipital paraesthesia possible. The range of amplitudes for Medtronic devices was 0.3-5.0 V (mean 2.4 V, median 1.5 V), pulse width 309-594 ls (mean 418 ls) and frequency 58-137 Hz (mean 69.5 Hz). For St Jude Medical devices the amplitude range was 0.5-2.7 mA (mean 2.5 mA, median 1.7 mA), frequency 70-177 Hz (mean 96 Hz) and pulse width 309-450 ls (mean 415 ls).
Adverse events
A total of 81 events were recorded, affecting a total of 35 patients (Table 5 ). The most common event was the need for battery replacement in 19 patients (37.3%); however, only six of these were deemed unexpected battery failure after less than 1 year. Thirty-eight events required surgical intervention, although when accounting for 'expected' battery depletion this fell to 19. One patient (2.0%) suffered lead migration and two (3.9%) suffered erosion of electrodes through the skin. One infection was reported (2.0%), which required medical intervention only.
Discussion
This is the largest series with a prolonged follow-up period for ONS in CCH. In line with previous series (Table S4) , we report that ONS appears to have a positive and sustained effect on otherwise refractory patients [9] [10] [11] [12] [13] [14] 18] . The most recent publications of long-term follow-up from Magis et al. and Leone et al. [19, 20] have both been on long-term follow-up of patients with CCH with ONS. Magis et al. [20] had a mean of 5.7 years follow-up in 10 patients and reported a 70% reduction in attack frequency but no change in preventative drug use. Leone et al. [19] described a responder rate of 66.7% in 30 patients with a median follow-up of 6.1 years with 10% of patients reducing preventative medications. In our group of 51 highly complex patients, after mean follow-up of 39.17 months there was a significant improvement in mean attack frequency with 24 patients remaining pain free for prolonged periods of time over follow-up. Overall, 52.9% of all patients exhibited response to ONS at final follow-up. There are a number of reasons why our response rate appears lower than in previous series. Firstly, our series had a complex cohort of patients. From available data, our patients had a longer duration of chronic disease, had failed more medications and over onethird had co-existing headache disorders, whereas previous series considered CCH alone. Our data suggest that there is no difference in outcomes of those with or without multiple headache types, a finding that is in opposition to general clinical belief. However, this needs to be clarified in larger cohorts of complex patients. Other factors include possible reporting bias in small series, e.g. the exclusion of patients whose devices were explanted, and the use of a trial stimulation period that we did not employ. Although no evidence exists for trial stimulation reliably selecting responders, removing those who do not respond may subject the remaining patients to positive selection bias.
Headache disability scales, affect and quality-of-life scales did show improvement with ONS but those in the quality-of-life measures were not significant in the whole cohort. However, subgroup analysis of responders versus non-responders showed a lack of improvement in any field in the non-responder cohort (Table S2 ). The failure to observe significant change across all quality-of-life measures despite improvements in attack frequency does not indicate lack of efficacy. Similar observations have been made previously in ONS for CM [21] and are thought to reflect a 'burden of normality' wherein patients have difficulty adjusting to the change in their new improved health status. Previous authors have also suggested that a lack of prolonged functional outcome is seen in the long term following ONS for CM, speculating that this is due to the loss of an initial 'honeymoon period' in patients [21] . Issues regarding the suitability of the scales for measuring headache populations have also been raised [22] . Specific to our cohort, given that 37.3% had multiple phenotypes that did not all necessarily respond to ONS, a significant proportion of patients would still exhibit a burden from these headaches, even if CCH had significantly improved. This is supported by a difference in disability scores in those with multiple phenotypes versus CCH alone ( Table 4) .
As in previous series [10, 12, 14, 23] , subjects reported a delay of several months before achieving a response (6.86 months) and suffered relapses within weeks of stopping stimulation. These observations suggest that there is a slow but reversible neuroplastic response to successful ONS.
The cost and adverse-event profile of ONS for headache treatment have been a cause for controversy in the past. A recent article estimated the mean treatment costs of ONS to be around £20 500 per case over a 2-year period [18] . Although the treatment cost is high, the direct cost of patients on society is significant. In our series, the cost per patient in the UK for triptans alone was over £9000 per year (based on mean triptan use per patient of 37 doses per month at cost of £20.50 per dose). Following ONS, we estimate that patients reduced this expense by £4886 per annum with responders saving an average of £7252 per year. Non-responders showed a smaller saving (£2224 per annum). This non-significant reduction reflects patients in this group having derived some benefit from the procedure even if they did not reach the dictated 50% improvement in attack frequency. Shorter or less painful attacks meant that patients avoided using triptans or oxygen. This saving combined with one-third of patients reducing preventative drugs and the significant improvements in quality-oflife measures all provide a positive balance to the initial cost of treatment. Using the above figures for the cost of the implant and changes in triptan doses, we estimate that the time to cost-effectiveness from reduction in triptan use alone is 3 years in responders (4 years in the whole group and 9 years in nonresponders).
Adverse events in our series were much lower than those described in previous cohorts. In small series lead migration rates vary from 7% to 50% [10, 12, 14, 16] , lead fracture rates from 10% to 15% [10, 14, 15] and infection rates from 10% to 20% [10, 14, 15] . The corresponding rates in our series were 2%, 0% and 2%, respectively. The primary reason for repeated surgery post-implant was to replace the battery (37.3%); however, the use of rechargeable batteries in recent years should lead to a decrease in surgical interventions and this is something that we intend to explore in future publications. Our implants were all conducted by a single highly skilled surgical team. A small number of experienced surgeons conducting larger numbers of procedures have been related to lower adverse event rates [24] and our data support this.
Weaknesses of the study include the lack of a placebo. This has been a major problem in ONS research, as it is believed that paraesthesia is a requirement of response. However, it is most unlikely that our observations are explained by placebo alone. The previous intractability, stable time to response across cohorts, sustained response after prolonged follow-up and relapse with ONS failure all argue against a pure placebo response. The placebo-controlled trials of ONS in migraine suggest a low placebo rate (6% [7] , 17.3% [8] and 20% [6] ) and there is no reason to expect different rates in cluster headache [25] .
Strengths of the study include the large sample, prolonged follow-up, prospective data collection and 'real-life' nature of the data. All subjects were patients in a single specialist center implanted due to clinical need in a healthcare system where ONS was only available as a last-line treatment. The group is different from some previous cohorts in its complex nature and highly intractable nature. A reduction in attack frequency of nearly 50% in such a highly intractable group, having suffered CCH for a mean of 7.88 years and having failed an average of 12.57 prior treatments, is a remarkable achievement.
Our group has recently published the outcomes of a similar group of 21 complex patients with CCH undergoing ventral tegmental area deep-brain stimulation, 29% of whom had failed ONS. A reduction in daily attack frequency of 60% was recorded with a 50% or more reduction in attack frequency achieved in 52% of patients. Given the similar response rate and the more invasive nature of deep-brain stimulation, it is clear that ONS should be considered first in CCH.
In conclusion, ONS can provide a marked and sustained benefit in control of highly intractable CCH even after a mean follow-up of 3 years. Adverse event rates are low when implants are conducted in highly specialist centers. The initial cost of implantation may be offset by the reduced need for acute medications and improved quality of life. Table S1 . Medications taken for cluster headache prior to occipital nerve stimulation. Table S2 . Headache disability and quality-of-life scales by treatment response. Table S3 . Headache outcome measures (a), patient estimate of improvement (b) and triptan use (c) by response to occipital nerve stimulation. Table S4 . Comparison of outcomes for occipital nerve stimulation in chronic cluster headache.
